Literature DB >> 7015789

DL-propranolol and chlorpromazine following admission for schizophrenia. A controlled comparison.

N J Yorkston, S A Zaki, M P Weller, J H Gruzelier, S R Hirsch.   

Abstract

Similar improvement followed when propranolol and chlorpromazine were randomly used as the first drug after admission. Forty-six patients with florid symptoms of schizophrenia were assigned at random to have either racemic propranolol (24) or chlorpromazine (22). Each individual's drug was adjusted to an optimal dose, and the progress of the groups was followed for 12 weeks. Thirty-five patients remained in the study for 6 weeks, and 27 for 12 weeks. By weeks 6 and 12 the total schizophrenia scores on a modified Brief Psychiatric Rating Scale had improved significantly when the results from both groups were combined. The numbers leaving the study, and the amount and rate of improvement, were similar for both groups, but with a possible advantage to chlorpromazine. Side-effects, which usually were mild, were commoner in the chlorpromazine group.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7015789     DOI: 10.1111/j.1600-0447.1981.tb00645.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  5 in total

Review 1.  [Use of certain cardiological drugs in the treatment of schizophrenia: review of the literature].

Authors:  P M Llorca; M A Wolf
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

2.  CBT for severe mental disorder: a good product that is in danger of being over-extended.

Authors:  Peter Tyrer
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

3.  [The EEG of patients with acute manic psychoses before, during and after treatment with high doses of d-propranolol and dl-propranolol (author's transl)].

Authors:  K Coulin; O Simon; H M Emrich; D von Zerssen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

4.  Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity.

Authors:  Robert D Oades; Bernd Röpcke; Uwe Henning; Ansgard Klimke
Journal:  Behav Brain Funct       Date:  2005-08-09       Impact factor: 3.759

Review 5.  Noradrenergic Modulation of Cognition in Health and Disease.

Authors:  Olga Borodovitsyna; Matthew Flamini; Daniel Chandler
Journal:  Neural Plast       Date:  2017-05-03       Impact factor: 3.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.